Recombinant KRT8 anticorps (full length)

N° du produit ABIN7878516

L’anticorps anti-KRT8 Monoclonal Souris est utilisé pour la détection de KRT8 dans des échantillons de Humain. Il a été validé pour WB et IHC (p).

Aperçu rapide pour Recombinant KRT8 anticorps (full length) (ABIN7878516)

Antigène: KRT8 (Keratin 8 (KRT8))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp KRT8 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: RKRT8-4209

Détail du produit anti-KRT8 anticorps

Épitope: full length

Fonction: Recombinant Cytokeratin 8 Antibody / KRT8 / CK18 (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: Recombinant full-length human KRT8 protein was used as the immunogen for the recombinant Cytokeratin 8 antibody.

Isotype: IgG2a, kappa

Information d'application

Indications d'application: Optimal dilution of the recombinant Cytokeratin 8 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the recombinant Cytokeratin 8 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur KRT8

Antigène: KRT8 (Keratin 8 (KRT8))

Autre désignation: Cytokeratin 8

Sujet: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

UniProt: P05787